India, May 14 -- GT Biopharma, Inc. (GTBP) announced that the first patient has been dosed in its Phase 1 basket trial evaluating GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors. The milestone marks the third TriKE candidate to enter clinical testing and expands the company's platform into a broader solid tumor opportunity.
The Phase 1a dose escalation portion of the study will primarily enroll patients with metastatic castration-resistant prostate cancer, a disease in which B7-H3 is expressed in more than 90 percent of tumors. Up to six dose levels will be tested to determine the maximum tolerated dose. Following this, the Phase 1b expansion will include patients with as many as seven different tumor types, in...